European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 1 , Pages 65-68 , November 2009

Serum C-reactive protein in the differential diagnosis of ovarian masses

  • Katrin Hefler-Frischmuth

      Affiliations

    • Department of Laboratory Medicine, Wilhelminenspital, Vienna, Austria
  • ,
  • Lukas A. Hefler

      Affiliations

    • Department of Obstetrics & Gynecology, Medical University of Vienna, Austria
    • Corresponding Author InformationCorresponding author at: Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Tel.: +43 1 40400 2962; fax: +43 1 40400 2911.
  • ,
  • Georg Heinze

      Affiliations

    • Department of Biostatistics, Medical University of Vienna, Austria
  • ,
  • Veronika Paseka

      Affiliations

    • Department of Obstetrics & Gynecology, Medical University of Vienna, Austria
  • ,
  • Christoph Grimm

      Affiliations

    • Department of Obstetrics & Gynecology, Medical University of Vienna, Austria
  • ,
  • Clemens B. Tempfer

      Affiliations

    • Department of Obstetrics & Gynecology, Medical University of Vienna, Austria

Received 11 April 2009 ,Revised 26 May 2009 ,Accepted 10 June 2009.

References 

  1. Tanir HM, Ozalp S, Yalcin OT, Colak O, Akcay A, Senses T. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol. 2003;23(3–4):271–274
  2. Hasholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Fateh-Moghadam A. Significance of the tumor markers CA 125 II, CA 72-4, CASA, and CYFRA 21-1 in ovarian carcinoma. Anticancer Res. 1994;14:2743–2746
  3. Hefler L, Tempfer C, Heinze G, et al. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer. 1999;8(5):855–859
  4. Tempfer C, Hefler L, Heinzl H, et al. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases. Br J Cancer. 1998;78(8):1108–1112
  5. Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989;56(2):126–130
  6. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: a causal factor?. Cardiovasc Res. 2006;71(1):30–39
  7. Eberhard OK, Langefeld I, Kuse ER, et al. Procalcitonin in the early phase after renal transplantation—will it add to diagnostic accuracy?. Clin Transplant. 1998;12(3):206–211
  8. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–111
  9. Hoffmann JA, Kafatos FC, Janeway CA, et al. Phylogenetic perspectives in innate immunity. Science. 1999;284:1313–1318
  10. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–111
  11. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–590
  12. Shimada H, Nabeya Y, Okazumi S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–252
  13. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–1864
  14. Miyata Y, Koga S, Nishikido M, et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology. 2001;58:161–164
  15. Kodama J, Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;82:107–110
  16. Hefler L, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Can Res. 2008;14(3):710–714

PII: S0301-2115(09)00413-8

doi: 10.1016/j.ejogrb.2009.06.010

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 1 , Pages 65-68 , November 2009